Board of Directors


Dr. Peter Burckhardt, EVA Basel, Investor Representative

Peter Burckhardt is President of the Board of „EVA – the Basel life sciences start-up agency“ since 2016. Before that he lead EVA for ten years as CEO. He is member of the board in several of EVA’s portfolio companies. Since 2009, Peter Burckhardt is president of the BioValley Business Angels Club BioBAC.

Peter Burckhardt joined Ciba-Geigy in 1984 where he started his career as a research chemist in Pharma Research. Later he held various management positions in research, development, manufacturing, and communications in Ciba-Geigy / Novartis. From 1996 – 1999 he was CEO of Novartis Animal Health Germany. From 2001 to 2006 he worked as a consultant in human resources.

Peter Burckhardt has an education as a chemist and achieved his PhD at the University of Basel.


Dr. Christoph Esslinger, CSO, Board Member

Christoph Esslinger is MEMO’s CSO, scientific founder and a pioneer of the discovery of therapeutic antibody candidates directly from human donors for immunotherapy of Alzheimer’s Disease and cancer. Prior to founding MEMO he held senior positions at CT Atlantic AG, Neurimmune AG and in academia.

Christoph Esslinger holds a diploma in Technical Biology from University of Stuttgart and a PhD in Molecular Immunology from the Ludwig Institute for Cancer Research, Lausanne Branch and University of Lausanne.


Dr. Dragan Gabulovski, Business Development & Strategy, Board Member

Dr. Dragan Grabulovski is an advisor in pharmaceutical biotechnology at Grabulovski Consulting Services (CH). He was previously chief scientific officer and co-founder of Covagen AG, a Swiss biotech company acquired in 2014 by Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson. As Covagen’s CSO, he was responsible for developing and overseeing the execution of the overall strategy for research and development. He was a main inventor of the Fynomer technology, established a portfolio of novel bispecific FynomAb product candidates and managed the internal and collaboration pipeline. As a member of Covagen’s executive management team, Dr. Grabulovski was instrumental in Covagen’s trade sale to Johnson & Johnson, and in the closing of Covagen’s CHF 45M ($44.5M) Series B round in 2014 with the participation of renowned investors such as GIMV, Edmond de Rothschild Investment Partners, Novartis Venture Fund and other prestigious funds. Dr. Grabulovski received his master’s degree in pharmaceutical sciences and Doctor of Sciences from ETH Zurich (CH). He is a co-author of several peer-reviewed articles, reviews, book chapters, poster abstracts, patent applications and granted patents.


Dr. Michael Sidler, Redalpine, Investor Representative

Partner at Redalpine. PhD in Life Sciences, Consultant at Boston Consulting Group, business developer at Prionics, M&A, investor, co-founder of Redalpine, CTI start-up coach.


Dr. Urs Spitz, Board Member

CEO & President Biosynth Group since 2004, Senior Manager Mettler Toledo, Strategy Consultant at Bain & Co.

Education: Research Fellow at MIT, Ph. D. in organic Chemistry The University of Chicago, MSc in organic Chemistry and IT University of Zürich.